Cynthia Carlsson, MD, MS, leads the AHEAD study at UW–Madison. The study is one of 100 global research sites currently offering a clinical study of the investigational treatment of lecanemab in people who may be at risk for memory problems. Carlsson spoke to multiple media outlets after the U.S. Food and Drug Administration’s (FDA) full approval of lecanemab was announced on July 6, 2023. She emphasized the treatment will only be approved for people who are diagnosed with mild cognitive impairment (MCI) or mild dementia and also meet other limited criteria. She said while this news is an important advance in the treatment of Alzheimer’s disease, researchers remain dedicated to discovering treatments that will stabilize the disease and ideally, prevent it from happening.
Read and watch these news stories:
“AHEAD study: Wisconsin participates in global effort to tackle Alzheimer's before symptoms show up” aired on WDJT CBS 58 in Milwaukee on July 11, 2023.
“FDA approval of groundbreaking Alzheimer's drug brings new hope to patients, caregivers” appeared on FOX 11 News on July 8, 2023
“FDA grants full approval for drug aiming to slow progression of Alzheimer’s” was published by NBC15 in Madison on July 7, 2023.
“Wisconsin doctor weighs in on new Alzheimer's drug” appeared on Spectrum News 1 on July 7, 2023.
“Madison school studying new Alzheimer’s drug” was published by WEAU 13 News on July 7, 2023.
“UW Health recruiting volunteers for clinical study of new Alzheimer's drug” appeared on WKOW 27 in Madison on July 7, 2023.
Related:
Nathaniel Chin, MD, discussed the promising new FDA-approved Alzheimer's drug, lecanemab, on the WPR program 'Central Time' on July 12, 2023. Listen to "Promising new FDA-approved Alzheimer's drug."
Listen to "Putting Lecanemab Into Practice: A Clinician’s Perspective on the New Alzheimer’s Treatment" on the Dementia Matters podcast with host Nathaniel Chin, MD, and guest Robert Przybelski, MD, MS.
Updated July 13, 2023.
